Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06971614 · ClinicalTrials.gov registry record · Phase 2
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
A Phase 2 study of Nonmuscle-invasive Bladder Cancer, sponsored by ImmVira Pharma Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 2
- Study locations
NCT06971614 is a Phase 2 study of Nonmuscle-invasive Bladder Cancer that is actively recruiting participants, run by ImmVira Pharma Co.. The registered enrollment target is 160 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06971614, a Phase 2 study of Nonmuscle-invasive Bladder Cancer, is actively recruiting participants, sponsored by ImmVira Pharma Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.
Conditions Studied
Interventions
- BIOLOGICAL T3011
Study Locations (2)
Arizona
- East Valley Urology Center - Queen Creek
Florida
- Florida Urology Partners, LLP - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-06-09 |
| Est. Completion | 2029-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06971614
The ClinicalTrials.gov registry entry for NCT06971614 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmVira Pharma Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nonmuscle-invasive Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which T3011 is the first listed.
NCT06971614 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06971614 about?
NCT06971614 is a clinical study titled "A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC". This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.
What is the current status of trial NCT06971614?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-06-09. Estimated completion is 2029-05-31.
What conditions does trial NCT06971614 study?
This clinical trial studies the following conditions: Nonmuscle-invasive Bladder Cancer.
What interventions are being tested in trial NCT06971614?
The interventions under investigation include: T3011 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06971614?
This trial is sponsored by ImmVira Pharma Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06971614 being conducted?
This trial has 2 study locations across Arizona, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonmuscle-invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.